Upload
roger961
View
383
Download
0
Embed Size (px)
Citation preview
New Insights intoCurrent MS Treatment
NMSS 20th Annual Research Symposium
Robert Shin, MDMaryland Center for MS
Impact of MS
• Leading non-traumatic cause of disability in young adults
• 250,000 to 350,000 affected in US*
• National cost of nearly $10 billion per year*
MS treatment 1990
MS treatment 1995
• Betaseron
MS treatment 2000
• Betaseron• Avonex• Copaxone
MS treatment 2005
• Betaseron• Avonex• Copaxone• Rebif• Novantrone• Tysabri
MS relapse rates
0
1
2
3
Betaseron Avonex Copaxone Rebif Tysabri* SENTINEL
placebodrug
-34%
-18%
-29%
-33%
-66% -54%
Current MS treatment
• Long-term efficacy• Safety/Tolerability• Early treatment• Head-to-head comparisons
Long-term efficacy
Long-term efficacy
• Ideally demonstrated by long term, controlled, comparative trials
• Such studies are impractical and possibly unethical
Extension studies
• PRISMS-4 (Rebif)– 7 to 8 years– Relapse rate 1.02 (crossover) vs 0.72 (44mcg)– Disability progression delayed by 18 months
• CHAMPS/CHAMPIONS (Avonex)– 5 years (extended to 10 years)– 44% reduction in CDMS at 1.5 years– 43% reduction in CDMS at 5 years
Long-term follow up
• Copaxone at 10 years– 108 on Copaxone therapy– 47 patients withdrew but were followed– 77 patients lost to follow up– 92% still walking without assistance
Long-term follow up
• Copaxone at 26* years– 46 followed– 28 patients withdrew– Average follow-up 10.5 years– 26.7% required assistance to walk
Long-term follow up
• Betaseron at 16 years– Identified 331/372 original patients– 51% (treated) vs 45% (placebo) ambulatory– 95% (treated) vs 83% (placebo) alive
Long-term follow up
• Avonex at 8 years– 160 patients, at least 2 years of Avonex– Sustained disability at 6 months predicted
disability at 8 years– 67% required assistance vs 24%
Neutralizing antibodies
• Protein or peptide based therapies may lead to the production of antibodies
• When antibodies block the biologic effect of the protein/peptide they are referred to as “neutralizing antibodies” (NAbs)
NAbs to beta interferon
• Betaseron (beta interferon 1b)– 28% to 47%
• Rebif (beta interferon 1a)– 13% to 24%
• Avonex (beta interferon 1a)– 2% to 6%
NAbs to beta interferon
• Typically appear within 3 to 18 months of initiation of treatment
• Reduction in efficacy may be delayed– Increased relapses– Increased MRI disease burden
• NAbs may disappear over time?
Conclusions
• Both beta interferon and glatiramer may be effective even after 5 to 15 years of treatment
• Neutralizing antibodies may appear in a minority of patients taking beta interferon
Safety/Tolerability
Safety issues: beta interferon• Depression/suicidal ideation• Leukopenia/thrombocytopenia• Liver enzyme elevation/hepatic injury• Thyroid dysfunction
• Pregnancy category C
Safety issues: beta interferon
• CBC and liver panel• Thyroid function tests
• Monitor for depression
Safety issues: glatiramer acetate
• Pregnancy category B
Rebif new formulation (RNF)
• Human serum albumin-free• Fetal bovine serum-free
• Reduced injection site reactions– 30.8% vs 85.8%
• Increase in flu-like side effects– 71% vs 48%
Conclusions
• Beta interferon and glatiramer are generally well-tolerated
Early treatment
Damage occurs early in MS
• Loss of N-acetylaspartate (NAA)• Diffusion tensor imaging (DTI) changes• White and gray matter magnetization
transfer ratio (MTR) abnormalities• Cerebral atrophy
• Time is brain!
MS treatments
• Reduce relapse rate• Reduce disability• Reduce new/active MRI lesions
• Earlier treatment is better!
Clinically Isolated Syndrome (CIS)
• A single episode of neurologic dysfunction caused by a single demyelinating lesion
• Optic neuritis• Brainstem syndrome• Spinal cord syndrome
CIS and MRI
• Patients with CIS are at increased risk to develop MS in the future
• An abnormal MRI is associated with a greatly increased risk to develop MS in the future
Question
• Can MS treatments benefit patients with CIS?
MS medications for CIS
• ETOMS (Early Treatment of MS)
• CHAMPS (Controlled High-risk Avonex MS Prevention Study)
• BENEFIT (Betaseron in Newly Emerging MS For Initial Treatment)
• PreCISe*
MS medications for CIS
• Randomized controlled trials consistently show fewer relapses among CIS patients treated with DMT
• Avonex and Betaseron now carry FDA indications for treatment of CIS
Conclusions
• Early treatment of MS is preferable to a delay in treatment
• CIS may be the first occurrence of MS
• MS treatments can be considered in CIS
Head-to-head comparisons
Need for direct comparison
• Different studies should not be compared to each other
• Different inclusion/exclusion criteria• Different outcome measures• Different populations
MS relapse rates
0
1
2
3
Betaseron Avonex Copaxone Rebif Tysabri* SENTINEL
placebodrug
-34%
-18%
-29%
-33%
-66% -54%
Beta interferons
• Betaseron (beta interferon 1b)• Avonex (beta interferon 1a)• Rebif (beta interferon 1a)
INCOMIN
• Beta interferon– Betaseron vs Avonex
• 188 patients followed for 2 years
• Betaseron 42% more likely to be relapse-free– 51% (Betaseron) vs 36% (Avonex)
• Betaseon more likely to be free of MRI activity– 55% (Betaseron) vs 26% (Avonex)
EVIDENCE
• Beta interferon 1a– 44 mcg tiw (Rebif) vs 30 mcg weekly (Avonex)
• 677 patients followed for 48 weeks
• 27% fewer relapses in Rebif group• One third reduction in MRI activity
Interferon vs glatiramer?
• Rebif vs Copaxone
• Almost 800 patients randomized• Followed for 96 weeks
• No significant difference*
Interferon vs glatiramer?
• CombiRX– Copaxone + Avonex– Copaxone + placebo– Avonex + placebo
• Is Copaxone + Avonex superior to either drug alone?
Conclusions
• Higher dose, higher frequence beta interferon appears to be more effective than lower dose interferon
• We do not know whether beta interferon or glatiramer acetate is more effective
Summary
• There have been great advances in treating MS over the past 15 years
• Clinical research has been crucial in helping us better understand and refine MS treatment